Search results
Veterinary care, animal hospitals are more scarce. That's bad for pets (and their owners)
USA TODAY via Yahoo News· 6 days agoThe AVMA is working to address those concerns and others through advocacy, scholarships and...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 3 days agoMeanwhile, Moderna is expanding its efforts in cancer treatment. The company is partnered with Merck...
MilliporeSigma invests in new life science site in South Korea
Homenewshere.com· 3 days agoMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, invests more than €300 million into a new Bioprocessing Production Center in Daejeon ...
Blackstone outbids Concord in $1.6 bln takeover battle for Hipgnosis Songs
Reuters· 6 days agoBlackstone's formal offer valued the music rights investor at $1.30 per share, the companies said,...
Ecstasy’s Odyssey | Mike Jay
New York Review of Books· 3 days agoWhat does science tell us about MDMA? Over the past decade psychedelic research has made a spectacular ascent from a network of marginalized enthusiasts...
CG follows big IPO with new results for bladder cancer drug
BioPharma Dive via Yahoo Finance· 2 days agoNewly disclosed Phase 3 results presented Friday match findings the biotech disclosed last year,...
Childhood Vaccination: Why It’s Important for Your Children and Community
KTBS Shreveport· 5 days agoThe increased risk of outbreaks can be largely attributed to the drop in pediatric vaccination rates...
Jemperli contends with blockbuster Keytruda in endometrial cancer
Clinical Trials Arena via Yahoo Finance· 4 days agoThe sBLA approval is based on the success of the Phase III RUBY Part I trial and places Jemperli in...
3 Investing Pros Lay Out Their Dividend Strategies—and Stock Picks
Barrons.com· 3 days agoIn February, Walmart announced a 9% dividend increase, its largest in more than a decade. Another of...
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
Zacks· 3 days agoCorcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.